29,377 Shares in Abbott Laboratories $ABT Purchased by Vertrix Wealth Management LLC

Vertrix Wealth Management LLC purchased a new stake in shares of Abbott Laboratories (NYSE:ABT) in the second quarter, HoldingsChannel.com reports. The institutional investor purchased 29,377 shares of the healthcare product maker’s stock, valued at approximately $2,666,000.

A number of other large investors have also added to or reduced their stakes in ABT. Allied Private Wealth LLC purchased a new stake in shares of Abbott Laboratories during the 2nd quarter worth approximately $45,000. Wealth Science Advisors LLC grew its holdings in shares of Abbott Laboratories by 509.1% in the second quarter. Wealth Science Advisors LLC now owns 8,345 shares of the healthcare product maker’s stock valued at $757,000 after purchasing an additional 6,975 shares in the last quarter. Exchange Bank purchased a new stake in Abbott Laboratories during the second quarter valued at $271,000. Jacobs & Co. CA lifted its position in Abbott Laboratories by 5.5% during the second quarter. Jacobs & Co. CA now owns 65,437 shares of the healthcare product maker’s stock valued at $5,937,000 after purchasing an additional 3,404 shares during the last quarter. Finally, Sax Wealth Advisors LLC grew its stake in shares of Abbott Laboratories by 6.3% in the 2nd quarter. Sax Wealth Advisors LLC now owns 7,046 shares of the healthcare product maker’s stock worth $639,000 after buying an additional 415 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 0.0%

Shares of NYSE ABT opened at $107.81 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The firm has a market capitalization of $186.56 billion, a price-to-earnings ratio of 34.89, a PEG ratio of 2.09 and a beta of 0.59. The stock has a 50 day moving average price of $95.51 and a 200 day moving average price of $99.87. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Diagnostics expansion strengthens growth outlook: Abbott is broadening its Diagnostics growth base through its Exact Sciences relationship and oncology testing expansion. Gains in cancer diagnostics and resilient routine testing are helping offset weaker respiratory-related demand, potentially making growth less dependent on COVID and respiratory testing. Here’s How ABT Broadens Diagnostics Growth Base With Oncology Expansion
• Positive Sentiment: Analysts remain bullish: Although ABT has lagged the broader market over the past year, Wall Street analysts continue to view the stock favorably and see further upside potential based on Abbott’s diversified healthcare portfolio and earnings durability. Abbott Stock: Is Wall Street Bullish or Bearish?
• Positive Sentiment: Reliable-growth investment case: An investor letter from Matrix Asset Advisors presents Abbott as a compelling long-term healthcare holding, emphasizing its dependable growth profile and diversified end markets. Broader nutritional-market growth could also support Abbott’s nutrition business over time. What Makes Abbott Laboratories a Compelling Investment Opportunity Global Nutritional Market Outlook
• Neutral Sentiment: Value debate remains: Comparisons with Envista (NVST) focus on which medical-products stock offers better value. The coverage may prompt investors to weigh Abbott’s premium valuation against its stronger diversification and consistency, but it does not represent a new company-specific catalyst. NVST vs. ABT: Which Stock Is the Better Value Option?
• Neutral Sentiment: Competitive backdrop: Analysts’ discussion of Abbott alongside other healthcare companies provides sector context, but no major change to Abbott’s outlook is indicated. Boston Scientific’s reduced 2026 guidance could be relatively favorable for Abbott if investors rotate toward companies with steadier execution, though it also underscores competitive pressures in medical devices. Analysts Offer Insights on Healthcare Companies

Wall Street Analyst Weigh In

A number of research analysts recently commented on ABT shares. Stifel Nicolaus lowered their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Evercore lowered their price objective on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. JPMorgan Chase & Co. boosted their target price on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Barclays decreased their price target on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a report on Monday, April 20th. Finally, BTIG Research lifted their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $118.17.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.